COMPOSITIONS AND METHODS FOR TREATING NIEMANN PICK C DISEASE

1 - 16 . (canceled)

17 . A method for decreasing cholesterol accumulation in a target cell of a subject in need thereof, the method comprising administering to the subject at least one PIKfyve inhibitor selected from the group consisting of apilimod or a pharmaceutically acceptable salt thereof, APY0201 ((E)-4-(5-(2-(3-methylbenzylidine)hydrazinyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)morpholine) and YM-201636 (6-amino-N-(3-(4-morpholinopyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl)phenyl)nicotinamide).

18 . The method of claim 17 , wherein the target cell is selected from a liver cell, a spleen cell, and a neural cell.

19 . The method of claim 18 , wherein the target cell is a liver or spleen cell.

20 . The method of claim 17 , wherein the subject is human.

21 . The method of claim 20 , wherein the subject in need is a subject having Niemann-Pick disease type C.

22 . The method of claim 21 , wherein the PIKfyve inhibitor is apilimod or a pharmaceutically acceptable salt thereof.

23 . The method of claim 22 , wherein the pharmaceutically acceptable salt of apilimod is selected from sulfate, citrate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate.

24 . The method of claim 23 , wherein the pharmaceutically acceptable salt of apilimod is selected from the group of selected from a chloride, methanesulfonate, fumarate, lactate, maleate, pamoate, phosphate, and tartrate.

25 . The method of claim 24 , wherein the pharmaceutically acceptable salt of apilimod is methanesulfonate.